HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1

Tumour-associated macrophages-derived CXCL8 determines immune evasion through autonomous PD-L1 expression in gastric cancer

(2019) Chao Lin et al.   GUT

Anti-PD-L1 treatment results in functional remodeling of the macrophage compartment

(2019) Huizhong Xiong et al.   CANCER RESEARCH

Wide Expression and Significance of Alternative Immune Checkpoint Molecules, B7x and HHLA2, in PD-L1–Negative Human Lung Cancers

(2018) Haiying Cheng et al.   CLINICAL CANCER RESEARCH

Prognostic Nomogram Based on Histological Characteristics of Fibrotic Tumor Stroma in Patients Who Underwent Curative Resection for Intrahepatic Cholangiocarcinoma

(2018) Chu‐Yu Jing et al.   ONCOLOGIST

Mismatch repair deficiency is a rare but putative therapeutically relevant finding in non-liver fluke associated cholangiocarcinoma

(2018) Benjamin Goeppert et al.   BRITISH JOURNAL OF CANCER

A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization

(2018) Miguel F. Sanmamed et al.   CELL

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

(2018) Peter Schmid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Programmed death ligand 1 expression in human intrahepatic cholangiocarcinoma and its association with prognosis and CD8+ T-cell immune responses

(2018) Ying Zhu et al.   Cancer Management and Research

Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non–Small-Cell Lung Cancer

(2017) Reinhard Büttner et al.   JOURNAL OF CLINICAL ONCOLOGY

Evaluation of the 8th edition American Joint Commission on Cancer (AJCC) staging system for patients with intrahepatic cholangiocarcinoma: A surveillance, epidemiology, and end results (SEER) analysis

(2017) Yuhree Kim et al.   JOURNAL OF SURGICAL ONCOLOGY

Capecitabine Extends Survival for Biliary Tract Cancer

(2017)   Cancer Discovery

Program Death 1 Immune Checkpoint and Tumor Microenvironment: Implications for Patients With Intrahepatic Cholangiocarcinoma

(2016) Faiz Gani et al.   ANNALS OF SURGICAL ONCOLOGY

Overexpression of interleukin-35 associates with hepatocellular carcinoma aggressiveness and recurrence after curative resection

(2016) Yi-Peng Fu et al.   BRITISH JOURNAL OF CANCER

HHLA2, a New Immune Checkpoint Member of the B7 Family, Is Widely Expressed in Human Lung Cancer and Associated with EGFR Mutational Status

(2016) Haiying Cheng et al.   CLINICAL CANCER RESEARCH

Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer

(2016) Kurt A. Schalper et al.   CLINICAL CANCER RESEARCH

CD163 + M2-type tumor-associated macrophage support the suppression of tumor-infiltrating T cells in osteosarcoma

(2016) Qinglin Han et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

HHLA2, a member of the B7 family, is expressed in human osteosarcoma and is associated with metastases and worse survival

(2016) Pratistha Koirala et al.   Scientific Reports

Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy

(2015) Suzanne L. Topalian et al.   CANCER CELL

PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma

(2015) F. Sabbatino et al.   CLINICAL CANCER RESEARCH

Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade

(2015) Philip J. Johnson et al.   JOURNAL OF CLINICAL ONCOLOGY

Combination cancer immunotherapies tailored to the tumour microenvironment

(2015) Mark J. Smyth et al.   Nature Reviews Clinical Oncology

Adjuvant Transarterial Chemoembolization Following Liver Resection for Intrahepatic Cholangiocarcinoma Based on Survival Risk Stratification

(2015) J. Li et al.   ONCOLOGIST

HHLA2 and TMIGD2: new immunotherapeutic targets of the B7 and CD28 families

(2015) Murali Janakiram et al.   OncoImmunology

Expression, Clinical Significance, and Receptor Identification of the Newest B7 Family Member HHLA2 Protein

(2014) M. Janakiram et al.   CLINICAL CANCER RESEARCH

Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma

(2014) John Bridgewater et al.   JOURNAL OF HEPATOLOGY

Prognostic Nomogram for Intrahepatic Cholangiocarcinoma After Partial Hepatectomy

(2013) Yizhou Wang et al.   JOURNAL OF CLINICAL ONCOLOGY

HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell function

(2013) R. Zhao et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Molecular Pathways: Next-Generation Immunotherapy--Inhibiting Programmed Death-Ligand 1 and Programmed Death-1

(2012) D. S. Chen et al.   CLINICAL CANCER RESEARCH

Identification of IGPR-1 as a novel adhesion molecule involved in angiogenesis

(2012) Nader Rahimi et al.   MOLECULAR BIOLOGY OF THE CELL

Intrahepatic Cholangiocarcinoma

(2009) Itaru Endo et al.   ANNALS OF SURGERY